Homology Medicines, Inc. (FIXX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 7.75 means the share price is 7.75 times one year of earnings per share.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHomology Medicines, Inc. (FIXX) trades at $15.78. Homology Medicines, Inc. is a genetic medicines company focused on developing treatments for rare genetic diseases. Sector: Healthcare.
Price as of · Last analyzed: May 9, 2026Analyst Coverage for FIXX: FIXX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Homology Medicines, Inc. (FIXX) Healthcare & Pipeline Overview
Homology Medicines, Inc. pioneers genetic medicines for rare diseases, leveraging its AAVHSc platform for in vivo gene therapy and editing. With a focus on single-injection treatments targeting various tissues, the company advances clinical programs like HMI-102 for PKU, positioning itself in the competitive biotechnology landscape.
What Is the Investment Thesis for FIXX?
Homology Medicines presents a focused investment opportunity within the genetic medicine space, specifically targeting rare genetic diseases. The company's proprietary AAVHSc platform offers a differentiated approach to in vivo gene therapy and editing. The ongoing Phase 2 clinical trial for HMI-102 in adults with PKU represents a near-term catalyst. Successful clinical trial outcomes and subsequent regulatory approvals could drive significant value. The company's pipeline, including HMI-103, HMI-202, HMI-203, and HMI-104, provides additional growth potential. However, the company faces risks associated with clinical trial success, regulatory hurdles, and competition from other gene therapy companies. The current market capitalization of $0.00B may reflect investor concerns about these risks, but also presents an opportunity for significant upside if the company achieves its clinical and regulatory milestones.
Based on FMP financials and quantitative analysis
FIXX Key Highlights
Gross Margin of 99.5% indicates efficient cost management in research and development activities.
- Profit Margin of 61.9% suggests effective monetization of existing assets and intellectual property.
- Phase 2 clinical trial of HMI-102 for PKU in adults represents a key milestone with potential for significant value creation.
- AAVHSc platform offers a differentiated approach to in vivo gene therapy and editing, potentially leading to more effective treatments.
- Market Cap of $0.00B may indicate undervaluation relative to pipeline potential, but also reflects risks associated with clinical trials and regulatory approvals.
Who Are FIXX's Competitors?
FIXX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BLUE bluebird bio, Inc. | $4.97 | 0.00% | $48.7M | — |
| SRPT Sarepta Therapeutics | $17.28 | -1.20% | $1.85B | — |
| RLYB Rallybio Corporation | $17.09 | +1.15% | $89.7M | 82 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.42 | -2.85% | $186M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.12 | -8.80% | $202M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.69 | +0.19% | $213M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.16 | -2.51% | $249M | 68 5-pillar |
| CRMD CorMedix Inc. | $7.27 | +0.15% | $571M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FIXX's Key Strengths?
Proprietary AAVHSc platform
- Focus on rare genetic diseases
- Strong intellectual property portfolio
- Experienced management team
What Are FIXX's Weaknesses?
Limited financial resources
- Dependence on clinical trial success
- Small number of employees
- Early stage of development
What Are the Key Risks for FIXX?
Clinical trial failures for HMI-102 or other pipeline programs.
- Regulatory delays or rejections for its gene therapies.
- Competition from other gene therapy companies.
- Product liability claims related to its gene therapies.
- Dependence on raising additional capital to fund its operations.
What Are FIXX's Competitive Advantages?
- Proprietary AAVHSc platform: Homology Medicines' AAVHSc platform provides a differentiated approach to in vivo gene therapy and editing.
- Intellectual property: The company has a strong intellectual property portfolio protecting its AAVHSc platform and gene therapy candidates.
- Expertise in gene therapy: Homology Medicines has a team of experienced scientists and clinicians with expertise in gene therapy development.
What Does FIXX Do?
Homology Medicines, Inc., founded in 2015 and headquartered in Bedford, Massachusetts, is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases. The company's core innovation lies in its proprietary adeno-associated virus vector (AAVHSc) platform. This platform enables the delivery of genetic medicines in vivo, utilizing both gene therapy and nuclease-free gene editing techniques. Homology Medicines' AAVHSc vectors are designed to target a range of disease-relevant tissues through a single injection, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. The company's lead product candidate is HMI-102, a gene therapy currently in Phase 2 pheNIX clinical trial for the treatment of phenylketonuria (PKU) in adults. In addition to HMI-102, Homology Medicines is developing HMI-103 for the treatment of PKU in pediatric patients, HMI-202 for metachromatic leukodystrophy, HMI-203 for mucopolysaccharidosis type II, and HMI-104 for paroxysmal nocturnal hemoglobinuria. Homology Medicines aims to address the unmet needs of patients with rare genetic diseases through its innovative gene therapy and gene editing approaches.
What Products and Services Does FIXX Offer?
- Develops gene therapies for rare genetic diseases.
- Utilizes its proprietary AAVHSc platform for in vivo gene delivery.
- Focuses on both gene therapy and nuclease-free gene editing.
- Targets a range of disease-relevant tissues through single injections.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Seeks regulatory approvals for its gene therapies.
- Commercializes its approved gene therapies.
How Does FIXX Make Money?
- Develops and patents novel gene therapies.
- Conducts research and development to advance its pipeline programs.
- Out-licenses or partners with other companies for commercialization.
- Generates revenue through product sales and licensing agreements.
What Industry Does FIXX Operate In?
Homology Medicines operates within the rapidly evolving biotechnology industry, specifically in the genetic medicine and gene therapy segment. The market for gene therapies is projected to experience substantial growth, driven by advancements in vector technology and increasing regulatory approvals. Competition is intense, with companies like Bluebird Bio and Sarepta Therapeutics also developing gene therapies for rare diseases. Homology Medicines differentiates itself through its AAVHSc platform, which aims to improve the safety and efficacy of gene delivery.
Who Are FIXX's Key Customers?
- Patients suffering from rare genetic diseases.
- Healthcare providers who treat patients with rare genetic diseases.
- Pharmaceutical companies that partner with Homology Medicines for commercialization.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Homology Medicines, Inc. stands at 230.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 52.2%, showing how much profit it generates from its asset base. FIXX trades at a trailing price-to-earnings ratio of 7.75, below the Healthcare sector average of ~21.10x. Its free cash flow yield is -16.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 18.5%, the inverse of the P/E and a quick read on earnings relative to price.
Forward Outlook
Wall Street analysts project Homology Medicines, Inc. revenue of about $2.0M for fiscal 2026, with EPS near $-0.94.
FIXX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary AAVHSc platform
- Focus on rare genetic diseases
- Strong intellectual property portfolio
- Experienced management team
Bear Case
- Limited financial resources
- Dependence on clinical trial success
- Small number of employees
- Early stage of development
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · May 2026
FIXX Latest News
No recent news available for FIXX.
FIXX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for FIXX.
Price Targets
Wall Street price target analysis for FIXX.
FIXX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for FIXX; grades run from A+ (80-100) to F (below 30).
Leadership: Paul Alloway
Unknown
Therefore, I cannot provide details about his career history, education, or previous roles.
Track Record: Information about Paul Alloway's track record is not available in the provided data. Therefore, I cannot provide details about his key achievements, strategic decisions, or company milestones under his leadership.
What Investors Ask About Homology Medicines, Inc. (FIXX) — Healthcare
What are the main risks for FIXX?
The main risks for Homology Medicines, Inc. include the inherent uncertainties of clinical trial outcomes, particularly for HMI-102 and other pipeline programs.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on provided data and may be limited.
- Market data may not be real-time.